Brokers Set Expectations for PTCT FY2025 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for PTC Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earn ($2.84) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $76.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.75) per share.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $0.15. The firm had revenue of $196.79 million during the quarter, compared to analysts’ expectations of $173.51 million. During the same period last year, the company earned ($1.76) EPS.

A number of other equities analysts have also recently weighed in on the company. The Goldman Sachs Group increased their price target on PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. Royal Bank of Canada raised shares of PTC Therapeutics from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $39.00 to $63.00 in a research note on Tuesday, December 3rd. Wells Fargo & Company boosted their price target on shares of PTC Therapeutics from $56.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. Robert W. Baird increased their price objective on shares of PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Finally, Citigroup boosted their target price on PTC Therapeutics from $26.00 to $32.00 and gave the company a “sell” rating in a research report on Wednesday, December 4th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $55.00.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock opened at $45.08 on Wednesday. The stock has a 50 day moving average of $45.25 and a 200 day moving average of $39.09. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -7.59 and a beta of 0.62. PTC Therapeutics has a fifty-two week low of $23.58 and a fifty-two week high of $54.16.

Hedge Funds Weigh In On PTC Therapeutics

Several large investors have recently bought and sold shares of PTCT. Charles Schwab Investment Management Inc. lifted its holdings in shares of PTC Therapeutics by 7.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock valued at $26,220,000 after purchasing an additional 47,902 shares during the last quarter. Two Sigma Advisers LP lifted its stake in PTC Therapeutics by 10.3% in the third quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company’s stock valued at $15,947,000 after buying an additional 40,300 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of PTC Therapeutics in the third quarter valued at approximately $698,000. Quest Partners LLC grew its position in shares of PTC Therapeutics by 433.9% during the third quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock worth $830,000 after acquiring an additional 18,171 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of PTC Therapeutics by 5.4% in the 3rd quarter. State Street Corp now owns 2,899,040 shares of the biopharmaceutical company’s stock valued at $107,554,000 after acquiring an additional 149,700 shares during the period.

Insider Buying and Selling at PTC Therapeutics

In related news, insider Neil Gregory Almstead sold 69,550 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $52.06, for a total value of $3,620,773.00. Following the completion of the transaction, the insider now directly owns 86,202 shares of the company’s stock, valued at $4,487,676.12. This represents a 44.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Christine Marie Utter sold 1,291 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $58,533.94. Following the sale, the chief accounting officer now directly owns 65,983 shares in the company, valued at approximately $2,991,669.22. The trade was a 1.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 211,737 shares of company stock valued at $10,920,687 in the last quarter. Corporate insiders own 5.50% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.